The purpose of this study is to determine the effect of Pandel® (hydrocortisone probutate cream) Cream 0.1% on the Hypothalamic Pituitary Adrenal (HPA) axis in pediatric and adult subjects with either psoriasis or atopic dermatitis involving greater than 20% body surface area.

Start Date01 Jun 2004

Sponsor / Collaborator

Fougera Pharmaceuticals, Inc.

100 Clinical Results associated with Hydrocortisone Probutate

100 Translational Medicine associated with Hydrocortisone Probutate

100 Patents (Medical) associated with Hydrocortisone Probutate

Literatures (Medical) associated with Hydrocortisone Probutate

01 Feb 2020·3 BiotechQ4 · ENGINEERING & TECHNOLOGY

Exploring genetic targets of psoriasis using genome wide association studies (GWAS) for drug repurposing

Q4 · ENGINEERING & TECHNOLOGY

Article

Author: Jeyakanthan, Jeyaraman ; Odumpatta, Rajasree ; Mohanapriya, Arumugam ; Ponnusamy, Nirmaladevi ; Nanda, Harshit

Psoriasis is a chronic inflammatory disease causing itching in the body and pain in the joints. Currently, no permanent cure is available at a commercial level for this disease. Genome wide association studies (GWAS) provide a deeper insight that helps in better understanding this disease and further possible cure of this disease. The major goal of the present study is to identify potent genetic targets of psoriasis disease using GWAS approach and identify drugs for repurposing. The methods used include GWAS catalogue, GeneAnalytics, canSAR protein annotation tool, VarElect, Drug bank, Proteomics database, ProTox software. By exploring GWAS catalogue, 126 psoriasis associated genes (PAG) were identified. 68 genes found to be druggable were obtained from canSAR protein annotation tool. Localization results depict that maximum genes are present in cytoplasmic cellular components. The superpathways obtained from GeneAnalytics resulted in involvement of these genes in the immune system, Jak/Stat pathway, Th17 and Wnt pathways. Two genes Interleukin 13 (IL13) and POLI are Food and Drug Administration (FDA) approved targets. Small compounds for these targets were analysed for drug-likeliness, toxicity and mutagenecity properties. The FDA approved drug pandel was found to possess desirable properties. The medications used for psoriasis causes mild to severe side effects and does not work well always. Hence we propose drug repurposing strategy to use existing drugs for new therapies. Therefore, the drug pandel could be explored further and repurposed to treat psoriasis.

01 Mar 2016·Die Pharmazie

Topical hydrocortisone 17-butyrate 21-propionate in the treatment of inflammatory skin diseases: pharmacological data, clinical efficacy, safety and calculation of the therapeutic index.

Review

Author: Abeck, D ; Torrelo, A ; Fölster-Holst, R

Hydrocortisone 17-butyrate 21-propionate (hydrocortisone buteprate, HBP) is a medium potent, non-halogenated double-ester of hydrocortisone with a favorable benefit/risk ratio for the treatment of inflammatory skin disorders. HBP is available as a 0.1% cream or ointment formulation. Good results were obtained with a once-daily topical treatment. HBP is characterized by a strong topical anti-inflammatory activity and weak systemic action. It is considered to have potency comparable to that of betamethasone 17-valerate (BV), but its systemic effects are less pronounced. HBP was shown to have a good efficacy in the treatment of various oozing and lichenified eczematous skin diseases including atopic dermatitis (AD) and in the treatment of psoriasis vulgaris. Even in very young children, HBP proved successful as an effective and safe drug. A therapeutic index of 2.0 can be attributed to this glucocorticoid. In this respect, there is no difference between topical HBP and other topical glucocorticoids with increased benefit/risk ratio, e.g. prednicarbate (PC), methylprednisolone aceponate (MPA) and mometasone furoate (MM).

01 Nov 2013·The Journal of DermatologyQ3 · MEDICINE

Role of macrophage infiltration in successful repigmentation in a new periphery‐spreading vitiligo lesion in a male Japanese patient

Q3 · MEDICINE

Article

Author: Tanemura, Atsushi ; Kimura, Masatomo ; Kawada, Akira ; Oiso, Naoki ; Kotobuki, Yorihisa ; Katayama, Ichiro

AbstractVitiligo is an acquired disorder in which depigmented macules result from mostly autoimmune loss of melanocytes. The initiating process in vitiligo has still been uncertain. Here, we report the case of a 19‐year‐old man with undetermined/unclassified vitiligo with a new periphery‐spreading vitiligo lesion on the right dorsal hand after rigorous sun exposure. Histopathological evaluation showed noticeable infiltration of CD68+ macrophages, moderate infiltration of CD3+ T cells, little infiltration of CD8+ T cells and CD11c+ myeloid dendritic cells, HMB45/CD11c double‐positive cells, and Melan‐A/MART1+ deposits in the dermis. We surmised that melanocyte‐derived deposits were mostly phagocytosed by CD68+ macrophages and were faintly phagocytosed by CD11c+ myeloid dendritic cells, referring distribution of CD68+ mononuclear cells and melanocyte biomarkers. Complete repigmentation was achieved following topical application of hydrocortisone butyrate propionate 0.1% ointment. We summarize that prompt clearance of debris by macrophages would be essential to an excellent prognosis of complete repigmentation.

100 Deals associated with Hydrocortisone Probutate

External Link

KEGG	Wiki	ATC	Drug Bank
D01886	Hydrocortisone Probutate	D07AA02 A01AC03 S02BA01 C05AA01 A07EA02 H02AB09 S01CB03 S01BA02 D07XA01	DB14543

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Inflammation	US	ANI Pharmaceuticals, Inc.	28 Feb 1997
Pruritus	US	ANI Pharmaceuticals, Inc.	28 Feb 1997
Skin Diseases	DE	Fougera Pharmaceuticals, Inc.	05 Feb 1997
Eczema	JP	Taisho Pharmaceutical Co., Ltd.	07 Oct 1982
Impetigo	JP	Taisho Pharmaceutical Co., Ltd.	07 Oct 1982
Insect Bites and Stings	JP	Taisho Pharmaceutical Co., Ltd.	07 Oct 1982
Lichen Planus	JP	Taisho Pharmaceutical Co., Ltd.	07 Oct 1982
Lupus Erythematosus, Discoid	JP	Taisho Pharmaceutical Co., Ltd.	07 Oct 1982
Prurigo	JP	Taisho Pharmaceutical Co., Ltd.	07 Oct 1982
Psoriasis	JP	Taisho Pharmaceutical Co., Ltd.	07 Oct 1982

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01137032 (CTgov)	Phase 4	Psoriasis \| Dermatitis, Atopic	19	Pandel Cream 0.1%	qavoztvpju(rffwnrlazp) = cmdmpwgvvs vzmfdbhqts (bsywuydxht, tlaozllask - ybjcaryucj) View more	-	29 Mar 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Hydrocortisone Probutate

Overview

Basic Info

Structure

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation